443 related articles for article (PubMed ID: 35869032)
1. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
[TBL] [Abstract][Full Text] [Related]
2. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
3. Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy.
Yang Y; Huang J; Liu M; Qiu Y; Chen Q; Zhao T; Xiao Z; Yang Y; Jiang Y; Huang Q; Ai K
Adv Sci (Weinh); 2023 Jan; 10(2):e2204365. PubMed ID: 36437106
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
5. Carrier-Free Nanomedicine for Cancer Immunotherapy.
Fu Y; Bian X; Li P; Huang Y; Li C
J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
Peng S; Xiao F; Chen M; Gao H
Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
Pan X; Ni S; Hu K
Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
[TBL] [Abstract][Full Text] [Related]
8. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
Xu T; Liu Z; Huang L; Jing J; Liu X
Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
[TBL] [Abstract][Full Text] [Related]
9. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies.
Zafar A; Hasan M; Tariq T; Dai Z
Bioconjug Chem; 2022 Jun; 33(6):1011-1034. PubMed ID: 34793138
[TBL] [Abstract][Full Text] [Related]
11. Remodeling tumor microenvironment with nanomedicines.
Martin JD; Miyazaki T; Cabral H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
[TBL] [Abstract][Full Text] [Related]
12. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Martin JD; Cabral H; Stylianopoulos T; Jain RK
Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
[TBL] [Abstract][Full Text] [Related]
13. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.
Mpekris F; Voutouri C; Panagi M; Baish JW; Jain RK; Stylianopoulos T
J Control Release; 2022 May; 345():190-199. PubMed ID: 35271911
[TBL] [Abstract][Full Text] [Related]
14. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
[TBL] [Abstract][Full Text] [Related]
16. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
Wei X; Wang J; Liang M; Song M
Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
[TBL] [Abstract][Full Text] [Related]
17. Thermal immuno-nanomedicine in cancer.
Yang Z; Gao D; Zhao J; Yang G; Guo M; Wang Y; Ren X; Kim JS; Jin L; Tian Z; Zhang X
Nat Rev Clin Oncol; 2023 Feb; 20(2):116-134. PubMed ID: 36604531
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy.
Guo Y; Hu P; Shi J
J Am Chem Soc; 2024 Apr; 146(15):10217-10233. PubMed ID: 38563421
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
Zhang Y; Li J; Pu K
Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
[TBL] [Abstract][Full Text] [Related]
20. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
Front Immunol; 2020; 11():601497. PubMed ID: 33408716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
